Durvalumab is a human immunoglobulin G1 kappa (IgG1ΞΊ) monoclonal antibody and a novel immune-checkpoint inhibitor for cancer treatment. Produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cell suspension culture, durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody that works to promote normal immune responses that attack tum...
Durvalumab is indicated for the treatment of adults with the following conditions:
Local Institution - 015, Omaha, Nebraska, United States
Local Institution - 016, Philadelphia, Pennsylvania, United States
Local Institution - 011, Duarte, California, United States
Penn State Cancer Institute, Hershey, Pennsylvania, United States
University of Iowa Hosptials and Clinics, Iowa City, Iowa, United States
Univerisity of Illinois Cancer Center, Chicago, Illinois, United States
Research Site, Hochiminh, Vietnam
The Christie, Manchester, United Kingdom
Royal Marsden Hospital, Sutton, United Kingdom
Aberdeen Royal Infirmary, Aberdeen, United Kingdom
BC Cancer Agency, Vancouver, British Columbia, Canada
Cross Cancer Institute, Edmonton, Alberta, Canada
London Regional Cancer Program of the Lawson Health Research Institute, London, Ontario, Canada
Centre Hospitalier de l'UniversitΓ© de MontrΓ©al, MontrΓ©al, Quebec, Canada
Martin King, Boston, Massachusetts, United States
University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Coborn Cancer Center at Saint Cloud Hospital, Saint Cloud, Minnesota, United States
Springfield Memorial Hospital, Springfield, Illinois, United States
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.